WORDS ON THE STREET 70th anniversary of Hanoi's Liberation Day Vietnam - Asia 2023 Smart City Summit Hanoi celebrates 15 years of administrative boundary adjustment 12th Vietnam-France decentrialized cooperation conference 31st Sea Games - Vietnam 2021 Covid-19 Pandemic
Home / Investment / News
Japan’s Taisho Group takes control of Vietnam’s DHG Pharmaceutical
Hai Yen 15:43, 2019/04/25
With an offering price of VND120,000 (US$5.14) per share, Taisho was expected to part away with at least VND2.47 trillion (US$105.84 million) to complete the deal.
Japan-based Taisho Pharmaceutical has lifted its holding in Vietnam’s Duoc Hau Giang (DHG) Pharmaceutical to over 50% and turns the latter into one of its subsidiaries, Taisho has said in a filling to the Ho Chi Minh City Stock Exchange (HoSE). 
 
Illustrative photo.
Illustrative photo.
Taisho purchased 20.6 million shares from DHG out of the 28.3 million shares on offer, taking its total shareholding to nearly 66.4 million, equivalent to 50.78% stake, according to the statement. 

With an offering price of VND120,000 (US$5.14) per share, higher than the current value at VND112,700 (US$4.83) recorded at the close on April 24, Taisho was expected to part away with at least VND2.47 trillion (US$105.84 million) to complete the deal. 

Behind Taisho, State Capital Investment Corporation (SCIC) is DHG’s second largest shareholder, holding 56.6 million shares or 43.31% stake, followed by Templeton Frontier Markets Fund (FTIF) and Norges Bank with 2.83% and 1.98% stakes, respectively. 

Taisho Pharmaceuticals, headquartered in Tokyo, is a leading Japanese pharmaceutical company specializing in the manufacturing of pharmaceutical products and non-prescription dietary supplements under well-known brands.

The Japanese company is pushing for market expansion in ASEAN countries and also in the East Asia. Currently, Taisho has overseas subsidiaries in Hong Kong, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, China, and the US, along with local productions bases in Malaysia, Vietnam, China, among others. 

In the first quarter of 2019, DHG’s revenue declined by 15% year-on-year to VND908 billion (US$38.9 million), while pre-tax profit was down 10% year-on-year to VND171 billion (US$7.32 million). 

In 2019, the local medicine maker targets revenue of VND3.94 trillion (US$168.83 million), up 1.6% year-on-year, and pre-tax profit at VND754 billion (US$32.3 million), up 3% year-on-year. 
Other news
18:03, 2025/02/22
Vietnam attracts South Korean tech investment at SEMICON Korea 2025
The event provided a platform for Vietnam to showcase its semiconductor potential and reaffirm its commitment to developing high-tech industries and strengthening international cooperation.
16:46, 2025/02/20
Swedish group plans US$1 billion investment in Binh Dinh recycling plant
By creating a large number of jobs and promoting a green economy, the initiative is important in establishing Vietnam as a global hub for the circular textile sector.
10:52, 2025/02/13
Samsung plans to invest in AI, semiconductors in Vietnam
Vietnam will continue improving its investment environment and driving strategic breakthroughs in order to usher in a new era of economic development.
17:20, 2025/02/07
Vietnam's data center construction costs among the lowest in Asia Pacific
The country has a lot of potential to become one of the most important data markets in the region.
21:05, 2025/02/03
Bright prospects for FDI inflows into Vietnam in 2025
Market size, growth potential, low labor costs, and stable political and social conditions continue to be Vietnam’s selling points in attracting foreign investors.
10:57, 2025/01/30
Foreign companies confirm investment expansion in Vietnam in 2025
Some foreign firms are optimistic about Vietnam's economic prospects in 2025 and plan to expand investment, focusing on sustainability across sectors.